Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910284 · ClinicalTrials.gov registry record
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
A clinical trial of Genital Herpes Simplex Type 2, sponsored by Genocea Biosciences.
- Completed
- Registry status
- 140
- Enrollment target
- 13
- Study locations
NCT02910284: Completed study of Genital Herpes Simplex Type 2, sponsored by Genocea Biosciences.
NCT02910284 is a study of Genital Herpes Simplex Type 2 that has completed, run by Genocea Biosciences. The registered enrollment target is 140 participants, below the 253-participant average among 3 other Genital Herpes Simplex Type 2 trials with a reported enrollment target (45% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910284, a study of Genital Herpes Simplex Type 2, has completed, sponsored by Genocea Biosciences.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.
Conditions Studied
Interventions
- BIOLOGICAL Observational
Study Locations (13)
California
- Medical Center for Clinical Research - San Diego
- Quest Clinical Research - San Francisco
Texas
- Tekton Research - Austin
- Center for Clinical Studies - Houston
Alabama
- University of Alabama - Birmingham - Birmingham
Illinois
- University of Illinois - Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Massachusetts
- The Fenway Institute - Boston
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-09-16 |
| Est. Completion | 2017-07-14 |
What the finished NCT02910284 record still lists
NCT02910284 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 253-participant average among 3 other Genital Herpes Simplex Type 2 trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Genital Herpes Simplex Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT02910284 lists 13 locations in 11 states (California, Texas, Alabama).
Frequently Asked Questions
What is clinical trial NCT02910284 about?
NCT02910284 is a clinical study titled "Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity". This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.
What is the current status of trial NCT02910284?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2016-09-16. Estimated completion is 2017-07-14.
What conditions does trial NCT02910284 study?
This clinical trial studies the following conditions: Genital Herpes Simplex Type 2.
What interventions are being tested in trial NCT02910284?
The interventions under investigation include: Observational (BIOLOGICAL).
Who is sponsoring clinical trial NCT02910284?
This trial is sponsored by Genocea Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02910284 being conducted?
This trial has 13 study locations across Alabama, California, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genital Herpes Simplex Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
ACTIVE NOT RECRUITING · Phase 1
-
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
COMPLETED · Phase 2
-
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI